RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that Company management will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, California, January 13-16, 2025. ADMA’s presentation will be on Monday, January 13, 2025, at 10:30 a.m. PT. A live audi ...

The biotech sector witnessed a see-saw performance in 2024. While the year started on a positive note, much of the gains slowed down in the second half of 2024. The downside in the second half was due to overall disappointing third-quarter results, guidance cuts and pipeline setbacks. The sector has declined 9.5% in the past six months, underperforming the S&P 500 index, as seen in the chart below.Image Source: Zacks Investment ResearchNonetheless, given the continuous need for innovative medicines, the bio ...

Cash on Hand Utilized to Repay $30 Million of Senior Secured Term Loan Facility to Ares Capital Lowers ADMA's Total Debt to $75 Million, a 29% Reduction Further Supports Earnings Growth Outlook RAMSEY, N.J. and BOCA RATON, Fla., Dec. 20, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced it has repaid $30 million from its original $ ...

It was a choppy ride for the biotech sector in 2024. While the year started on a positive note, much of the gains were pared thereafter, and the sector is down 10.5% as of now. New drug approvals and a surge in mergers and acquisitions (M&A) activity were expected to keep the sector going in 2024, but a slowdown in collaboration deals despite a drop in interest rates and market volatility hit hard.Nonetheless, given the continuous need for innovative medical treatments, irrespective of the state of the econ ...

Shares of Adma Biologics (ADMA) have gained 5.8% over the past four weeks to close the last trading session at $19.92, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25 indicates a potential upside of 25.5%. The average comprises four short-term price targets ranging from a low of $24 to a high of $26, with a standard deviation of $0.82. While the lowest estimate indicates an ...

Shares of Adma Biologics (ADMA) have gained 20.7% over the past four weeks to close the last trading session at $19.04, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $25 indicates a potential upside of 31.3%. The mean estimate comprises four short-term price targets with a standard deviation of $0.82. While the lowest estimate of $24 indicates a 26.1% increase from the current ...

LOS ANGELES, Nov. 8, 2024 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or "the Company") (NASDAQ: ADMA) for violations of the securities laws.According to the Complaint, the Company made false and misleading statements to the market. ADMA Biologics admitted the abrupt resignation of its independent outside auditor, CohnReznick LLP., on October 9, 2024. The Company ...

NEW YORK, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into ADMA Biologics, Inc. (NASDAQ: ADMA) for potential violations of the federal securities laws. If you invested in ADMA Biologics, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/adma-biologics-inc. Why Did ADMA Biologics’s Stock Drop? ADMA Biologics is an end-to-end commercial biopharmaceutical company that manufactures, ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Skyler Bloom – Senior Director, Business Development & Corporate Strategy Adam Grossman – President and Chief Executive Officer Brad Tade – Chief Financial Officer and Treasurer Conference Call Participants Kristen Kluska – Cantor Fitzgerald Anthony Petrone – Mizuho Group Gary Nachman – Raymond James Operator Thank you for standing by. My name is Celine and I will be your conference operator ...

Adma Biologics (ADMA) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15.38%. A quarter ago, it was expected that this infectious disease drug developer would post earnings of $0.08 per share when it actually produced earnings of $0.13, delivering a surprise of 62.50%. Over the last ...